l dopa

L-DOPA belongs to the category of dopamine precursors, serving as an orally active neurotransmitter metabolic precursor capable of crossing the blood-brain barrier and undergoing conversion to dopamine within the brain. The compound exhibits anti-hyperalgesic properties and finds application in Parkinson's disease research as well as in the induction of disease models.

L-DOPA methyl ester (LDME) is an agonist of dopamine D1 receptor.

6-Hydroxy-L-DOPA is the 6-hydroxy derivative of the amino acid L-DOPA with neurotoxic properties. Exogenously administered 6-Hydroxy-L-DOPA is biotransformed by an amino acid decarboxylase to the highly potent and catecholamine-selective neurotoxin, 6-Hydroxydopamine.

DPBX-L-Dopa is a boron-containing dopa-derivative, acting as a bladder relaxant through non-catecholamine receptors.

3-O-methyl-L-DOPA is a metabolite of L-DOPA , produced by the activity of catechol O-methyltransferase. 3-O-methyl-L-DOPA may have effects of its own or it may compete with the actions of L-DOPA.

[18F]-Labeled L-dopa precursor is used in the synthesis of 18F-labeled L-dopa[1].

L-Dopa precursor-1 (Compound 5a) is the precursor of 18F-L-Dopa. Serving as the core basis for a radiolabeling precursor, L-Dopa precursor-1 facilitates the introduction of non-metal radioactive elements through radiolabeling reactions. This compound can be utilized in studies related to renal denervation (RDN) surgery for refractory hypertension and chronic kidney disease.

N-Octanoyl dopamine surpasses dopamine in preserving the contractile function of donor hearts from brain-dead individuals. Additionally, N-Octanoyl dopamine inhibits cytokine production in activated T cells and reduces the expression of MHC-II and adhesion molecules in endothelial cells stimulated by IFNγ.

D-α-Methyl DOPA is an inhibitor of DQ8 peptide binding to MHC class II molecules. By occupying a binding site in the DQ8 peptide groove, D-α-Methyl DOPA prevents the DQ8 peptide from associating with MHCII molecules. This action blocks presentation to CD4+ T cells, thereby slowing or hindering the onset or progression of type 1 diabetes or celiac disease.

NMI 8739 (n-docosahexaenoyl dopamine) is an agonist of D2 autoreceptor. NMI 8739 reduces NO production and elicits concentration-dependent suppression of CCL-20, MCP-1 and IL-6 release.

PALDA (N-Palmitoyl dopamine) is a fatty acid dopamine found in the mammalian brain that is inactive against TRPV1 and inactivates at TRPV(1)R. It is used in the study of duodenal ulcers.

Methyldopa (MK-351), an alpha-adrenergic agonist (selective for α2-adrenergic receptors) psychoactive medicine, is served as an antihypertensive or sympatholytic.

Methyldopa hydrate (MK-351 hydrate) is a DOPA decarboxylase inhibitor and indirect α2-adrenergic receptor agonist used to treat hypertension. It inhibits the sympathetic nervous system, decreases production of dopamine, norepinephrine, and epinephrine, and exhibits NO-dependent sedative activity.

DL-Dopa is a phenylalanine beta-hydroxylated derivative.

3-Methoxytyramine hydrochloride (3-O-methyl Dopamine hydrochloride) is an inactive metabolite of dopamine which can activate trace amine associated receptor 1 (TAAR1). 3-methoxytyramine can be found primarily in human brain and most tissues tissues; and in blood, cerebrospinal fluid (csf) or urine. Within a cell, 3-methoxytyramine is primarily located in the cytoplasm.

3-Methoxytyramine (3-O-methyl Dopamine) is a cellular metabolite of dopamine (3-hydroxytyramine), a neuromodulator that induces behavioral effects, induces significant ERK and CREB phosphorylation, and is capable of inducing a complex set of aberrant involuntary movements in acutely depleted dopamine-containing mice.

4-O-Methyldopamine hydrochloride ,with CAS No. 645-33-0, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. 4-O-Methyldopamine hydrochloride provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Etilevodopa is an ethyl-ester prodrug of Levodopa which is used for the treatment of Parkinson's disease (PD). It is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Levodopa is the direct precursor of dop

L-(-)-α-Methyldopa hydrochloride is an alpha-adrenergic agonist psychoactive drug. It is used as a sympatholytic or antihypertensive. Methyldopa has a dual mechanism of action. It is a competitive inhibitor of the enzyme DOPA decarboxylase, which converts

Etilevodopa hydrochloride (L-DOPA ethyl ester) is a prodrug of levodopa. It also has greater gastric solubility and significant brain penetration.

Trans-Clovamide (trans-Clovamide) is a naturally occurring caffeoyl conjugate identified in the antioxidant polyphenolic fraction of cocoa (T. cacao L.) Trans-Clovamide is a potent antioxidantand that has shown neuroprotective effects (EC50s = 0.9-3.7 µM) in several in vitro models of neuronal death. Trans-Clovamide is an excellent ROS and oxygen radical scavenger and also has anti-inflammatory and neuroprotective effects. Clovamide is an anti-microbial with activity against the human pathogens influenza A subtype H5N1, Trypanosoma evansi, and Heliobacter pylori.

SD-1077 is a deuterium containing levodopa. SD-1077 has been shown in preclinical models to improve the half-life of dopamine in the brain resulting in a prolonged treatment effect.

3-(2,4-Dihydroxyphenyl)propanoic acid (Hydroumbellic acid) is a predicted metabolite generated by BioTransformer1 from the metabolism of 3-(2,4-dihydroxyphenyl)prop-2-enoic acid. It is produced by the abkar1 enzyme via a reduction-of-alpha-beta-unsaturated-compounds-pattern1 reaction in human gut microbiota.

3-O-Methyldopa (3-OMD) is the primary metabolite of L-DOPA formed by COMT. It serves as a clinical biomarker in Parkinson's disease research to monitor L-DOPA metabolism and pharmacological response.